Indeed, immune checkpoint inhibitor (ICI) therapy aimed at blocking the PD-1/PD-L1 axis was approved by the FDA in 2014 for the treatment of PCM and is now being used as a standard of care for patients with irresectable stage III or stage IV disease, and as adjuvant therapy in stage III melanoma (3). The gene discussed is CD274; the disease is melanoma.